Enanta Pharmaceuticals Priced, Nasdaq: ENTA
Biotech focused on developing small molecule drugs to use against hepatitis C.
Industry: Health Care
First Day Return: +22.7%
ENTA
Biotech focused on developing small molecule drugs to use against hepatitis C.
| IPO Data | |
|---|---|
| IPO Date | 03/20/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $56 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Watertown, MA, United States |
| Founded | 1996 |
| Employees at IPO | 39 |
| Website www.enanta.com | |
IPO News for Enanta Pharmaceuticals
Enanta Pharmaceuticals (ENTA) Performance
